Abstract
Objectives The objective of the study was to estimate how the time elapsed from previous antibiotic use is associated with antibiotic resistance.
Methods Data comprised electronic medical records of all patients in an Israeli hospital who had a positive bacterial culture between 2016-19. These included susceptibility testing results, and clinical and demographic data. Mixed-effects time-varying logistic models were fitted to estimate the association between time elapsed since last use of aminoglycosides and gentamicin resistance (n = 13,095), cephalosporins and ceftazidime resistance (n = 13,051), and fluoroquinolones and ciprofloxacin resistance (n = 15,364), while adjusting for multiple covariates.
Results For all examined antibiotics, previous antibiotic use had a statistically significant association with resistance (p < 0.001). These associations exhibited a clear decreasing pattern over time, which we present as a flexible function of time. Nonetheless, previous antibiotic use remained a significant risk factor for resistance for at least 180 days, with adjusted odds ratios of 1.94 (95% CI 1.40-2.69), 1.33 (95% CI 1.10-1.61), and 2.25 (95% CI 1.49-3.41), for gentamicin, ceftazidime and ciprofloxacin, respectively.
Conclusions The association between prior antibiotic use and resistance decreases over time. Commonly used cut-offs for prior antibiotic use can either misclassify patients still at higher risk, when too recent; or provide a diluted estimate of the effects of antibiotic use on future resistance, when too distant. Hence, prior antibiotic use should be considered as a time-dependent risk factor for resistance, both in epidemiological research and clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Israel Science Foundation (ISF 1286/21).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Meir Medical Center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Subgroup analyses were added
Data Availability
The data and computing code are not available for replication because they are protected under medical confidentiality.
